Ascelia Pharma
Developing novel drugs for rare cancer conditions, including an oral MRI contrast agent.
ACE | ST
Overview
Corporate Details
- ISIN(s):
- SE0010573113 (+2 more)
- LEI:
- 5493002YR9VCJJPWYN08
- Country:
- Sweden
- Address:
- Hyllie Boulevard 34, 215 32 Malmö
- Website:
- https://www.ascelia.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Ascelia Pharma is a biotechnology company dedicated to the development and commercialization of novel drugs for rare cancer conditions (orphan oncology). The company's vision is to address unmet medical needs by advancing a portfolio of innovative therapies with clear development and market pathways. Its lead product candidate, Orviglance, is a novel manganese-based oral contrast agent for magnetic resonance imaging (MRI) designed to improve the detection of liver metastases in cancer patients with severely impaired kidney function, for whom gadolinium-based agents are contraindicated. The company is focused on progressing its pipeline through clinical development and towards regulatory approval.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Ascelia Pharma and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-02 16:10 |
Share Issue/Capital Change
Fenja Capital II A/S påkallar konvertering av samtliga utestående konvertibler …
|
Swedish | 190.4 KB | |
| 2025-09-02 16:10 |
Share Issue/Capital Change
Fenja Capital II A/S Requests Conversion of All Outstanding Convertibles for a …
|
English | 190.1 KB | |
| 2025-08-21 07:30 |
Interim Report
|
Swedish | 4.5 MB | |
| 2025-08-21 07:30 |
Interim Report
|
English | 4.4 MB | |
| 2025-05-16 07:30 |
Interim Report
|
Swedish | 4.4 MB | |
| 2025-05-16 07:30 |
Investor Presentation
|
English | 4.4 MB | |
| 2025-05-07 16:30 |
Post-Annual General Meeting Information
Kommuniké från årsstämma den 7 maj 2025 i Ascelia Pharma AB
|
Swedish | 193.2 KB | |
| 2025-05-07 16:30 |
Post-Annual General Meeting Information
Bulletin from the Annual General Meeting in Ascelia Pharma AB on 7 May 2025
|
English | 192.7 KB | |
| 2025-04-30 11:30 |
Declaration of Voting Results & Voting Rights Announcements
Change in Number of Shares and Votes in Ascelia Pharma AB
|
English | 185.4 KB | |
| 2025-04-30 11:30 |
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Ascelia Pharma AB
|
Swedish | 185.6 KB | |
| 2025-03-18 22:05 |
Legal Proceedings Report
Ascelia Pharma meddelar positivt utfall från FDA-möte och bekräftar planen att …
|
Swedish | 190.7 KB | |
| 2025-03-18 22:05 |
Legal Proceedings Report
Ascelia Pharma Announces Positive Outcomes of FDA Meeting and Confirms Plan to …
|
English | 190.5 KB | |
| 2025-02-25 14:45 |
Post-Annual General Meeting Information
Kommuniké från extra bolagsstämma den 25 februari 2025 i Ascelia Pharma AB
|
Swedish | 191.1 KB | |
| 2025-02-25 14:45 |
Post-Annual General Meeting Information
Bulletin from the Extraordinary General Meeting in Ascelia Pharma AB on 25 Febr…
|
English | 190.5 KB | |
| 2025-02-12 21:30 |
Board/Management Information
Nomination Committee Appointed for AGM 2025 in Ascelia Pharma AB
|
English | 191.2 KB |
Automate Your Workflow. Get a real-time feed of all Ascelia Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Ascelia Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-22 | Marie Birgitta Källström | Other | Other | 18,752 | 40,316.80 SEK |
| 2025-04-15 | Niels Mengel | Other | Other | 92,304 | 198,453.60 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 50,000 | 107,500.00 SEK |
| 2025-04-15 | Carin Linde | Other | Other | 40,328 | 86,705.20 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 21,688 | 46,629.20 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 20,472 | 44,014.80 SEK |
| 2025-04-15 | Julie Brogren | Other | Other | 18,000 | 38,700.00 SEK |
| 2025-04-15 | Peter Benson | Other | Other | 6,152 | 13,226.80 SEK |
| 2024-09-03 | KIBEGEON | Other | Sell | 913,545 | 150,917.63 SEK |
| 2024-09-03 | Niels Mengel | Other | Sell | 131,965 | 17,815.28 SEK |
